Journal Article
. 2014 Apr; 1(4):229-34.
doi: 10.1158/2326-6066.CIR-13-0020.

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

Derek Ng Tang 1 Yu Shen  Jingjing Sun  Sijin Wen  Jedd D Wolchok  Jianda Yuan  James P Allison  Padmanee Sharma  
Affiliations
  • PMID: 24777852
  •     26 References
  •     87 citations

Abstract

Pharmacodynamic biomarkers can play an important role in understanding whether a therapeutic agent has "hit its target" to impact biologic function. A pharmacodynamic biomarker for anti-CTLA-4 therapy remains to be elucidated. We previously reported that anti-CTLA-4 therapy increases the frequency of CD4 T cells expressing the inducible costimulator (ICOS) molecule. To determine whether the frequency of ICOS(+) CD4 T cells could be used as a pharmacodynamic biomarker for anti-CTLA-4 therapy, we carried out flow cytometric studies and statistical analyses on data from 56 individuals, which included 10 healthy donors, 36 patients who received anti-CTLA-4 monoclonal antibody (mAb), and 10 patients who received treatment with a different immunomodulatory agent (gp100 DNA vaccine). After treatment with anti-CTLA-4 mAb (ipilimumab; Bristol-Myers Squibb), we detected a statistically significant increase in the frequency of ICOS(+) CD4 T-cells. After two doses of anti-CTLA-4 therapy, the assay was found to have an estimated specificity of 96% [95% confidence interval (CI), 88-100] and sensitivity of 71% (95% CI, 54-85), with positive expression defined as a frequency that is more than the upper bound of 95% CI among baseline samples from all subjects. Our data suggest that an increased frequency of ICOS(+) CD4 T cells measured by flow cytometry can be used as a reproducible pharmacodynamic biomarker to indicate biologic activity in the setting of anti-CTLA-4 therapy, which should enable appropriate immune monitoring to determine whether patients receiving anti-CTLA-4 monotherapy or combination treatment strategies are having an adequate biologic response.

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A A Hurwitz, B A Foster, +5 authors, J P Allison.
Cancer Res, 2000 May 16; 60(9). PMID: 10811122
Highly Cited.
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Eric J Small, N Simon Tchekmedyian, +3 authors, James P Allison.
Clin Cancer Res, 2007 Mar 17; 13(6). PMID: 17363537
Highly Cited.
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Yvonne M Saenger, Jedd D Wolchok.
Cancer Immun, 2008 Jan 18; 8. PMID: 18198818    Free PMC article.
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.
M Zahidunnabi Dewan, Ashley E Galloway, +4 authors, Sandra Demaria.
Clin Cancer Res, 2009 Aug 27; 15(17). PMID: 19706802    Free PMC article.
Highly Cited.
Costimulatory regulation of T cell function.
C A Chambers, J P Allison.
Curr Opin Cell Biol, 1999 Apr 21; 11(2). PMID: 10209159
Review.
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
M F Krummel, J P Allison.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676074    Free PMC article.
Highly Cited.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Hong Chen, Chrysoula I Liakou, +8 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2009 Feb 10; 106(8). PMID: 19202079    Free PMC article.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Bradley C Carthon, Jedd D Wolchok, +8 authors, Padmanee Sharma.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460488    Free PMC article.
Highly Cited.
ICOS co-stimulatory receptor is essential for T-cell activation and function.
C Dong, A E Juedes, +4 authors, R A Flavell.
Nature, 2001 May 09; 409(6816). PMID: 11343121
Highly Cited.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
T-cell co-stimulation through B7RP-1 and ICOS.
S K Yoshinaga, J S Whoriskey, +23 authors, G Senaldi.
Nature, 2000 Jan 05; 402(6763). PMID: 10617205
Highly Cited.
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
A Hutloff, A M Dittrich, +4 authors, R A Kroczek.
Nature, 1999 Feb 04; 397(6716). PMID: 9930702
Highly Cited.
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Brian A Ginsberg, Humilidad F Gallardo, +13 authors, Jedd D Wolchok.
Clin Cancer Res, 2010 Jul 22; 16(15). PMID: 20647477    Free PMC article.
CD28/B7 system of T cell costimulation.
D J Lenschow, T L Walunas, J A Bluestone.
Annu Rev Immunol, 1996 Jan 01; 14. PMID: 8717514
Highly Cited. Review.
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Tihui Fu, Qiuming He, Padmanee Sharma.
Cancer Res, 2011 Jun 29; 71(16). PMID: 21708958
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Alan Korman, Michael Yellin, Tibor Keler.
Curr Opin Investig Drugs, 2005 Jul 02; 6(6). PMID: 15988909
Review.
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Robert H Vonderheide, Patricia M LoRusso, +9 authors, Susan M Domchek.
Clin Cancer Res, 2010 May 19; 16(13). PMID: 20479064
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.
Raju R Raval, Andrew B Sharabi, +2 authors, Padmanee Sharma.
J Immunother Cancer, 2014 Jun 03; 2. PMID: 24883190    Free PMC article.
Review.
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Sonia Guedan, Xi Chen, +9 authors, Carl H June.
Blood, 2014 Jul 06; 124(7). PMID: 24986688    Free PMC article.
Highly Cited.
Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.
Shirin Karimi, Subhasis Chattopadhyay, Nitya G Chakraborty.
Immunology, 2014 Sep 23; 144(2). PMID: 25243729    Free PMC article.
Review.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F Stephen Hodi, Sandra Lee, +7 authors, John M Kirkwood.
JAMA, 2014 Nov 05; 312(17). PMID: 25369488    Free PMC article.
Highly Cited.
The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells.
Peter T Sage, Alison M Paterson, Scott B Lovitch, Arlene H Sharpe.
Immunity, 2014 Dec 20; 41(6). PMID: 25526313    Free PMC article.
Highly Cited.
The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
Michelle H Nelson, Sreenath Kundimi, +9 authors, Chrystal M Paulos.
J Immunol, 2015 Jan 13; 194(4). PMID: 25576595    Free PMC article.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
Biomarkers for glioma immunotherapy: the next generation.
Jennifer S Sims, Timothy H Ung, +2 authors, Jeffrey N Bruce.
J Neurooncol, 2015 Mar 01; 123(3). PMID: 25724916    Free PMC article.
Review.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Review.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Mechanisms of action of therapeutic antibodies for cancer.
J M Redman, E M Hill, D AlDeghaither, L M Weiner.
Mol Immunol, 2015 Apr 29; 67(2 Pt A). PMID: 25911943    Free PMC article.
Review.
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.
Michael A Postow, Manuarii Manuel, +9 authors, Jedd D Wolchok.
J Immunother Cancer, 2015 Jun 19; 3. PMID: 26085931    Free PMC article.
Highly Cited.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
Intellectual property issues of immune checkpoint inhibitors.
Ulrich Storz.
MAbs, 2015 Oct 16; 8(1). PMID: 26466763    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Review.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
Review.
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Axel Hoos.
Nat Rev Drug Discov, 2016 Mar 12; 15(4). PMID: 26965203
Highly Cited.
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
Daniel H Sterman, Evan Alley, +21 authors, Steven M Albelda.
Clin Cancer Res, 2016 Mar 13; 22(15). PMID: 26968202    Free PMC article.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
Review.
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Jon Bjoern, Nikolaj Juul Nitschke, +3 authors, Inge Marie Svane.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141381    Free PMC article.
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Alexander Martens, Kilian Wistuba-Hamprecht, +15 authors, Benjamin Weide.
Clin Cancer Res, 2016 May 14; 22(19). PMID: 27169993    Free PMC article.
Highly Cited.
Monitoring immune responses in the tumor microenvironment.
Jennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, Padmanee Sharma.
Curr Opin Immunol, 2016 May 31; 41. PMID: 27240055    Free PMC article.
Review.
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Heather L McArthur, Adi Diab, +27 authors, Larry Norton.
Clin Cancer Res, 2016 Nov 05; 22(23). PMID: 27566765    Free PMC article.
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.
Joana Felix, Jérome Lambert, +13 authors, Hélène Moins-Teisserenc.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622012    Free PMC article.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Sumit K Subudhi, Ana Aparicio, +14 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(42). PMID: 27698113    Free PMC article.
Highly Cited.
Gene-expression profiling to predict responsiveness to immunotherapy.
N B Jamieson, A V Maker.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834354    Free PMC article.
Review.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Review.
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
David Y Oh, Jason Cham, +5 authors, Lawrence Fong.
Cancer Res, 2016 Dec 30; 77(6). PMID: 28031229    Free PMC article.
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.
Xiao Hu, Xikui Liu, +19 authors, Laura L Carter.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123897    Free PMC article.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Jianjun Gao, John F Ward, +16 authors, Padmanee Sharma.
Nat Med, 2017 Mar 28; 23(5). PMID: 28346412    Free PMC article.
Highly Cited.
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
Yago Pico de Coaña, Maria Wolodarski, +9 authors, Rolf Kiessling.
Oncotarget, 2017 Apr 21; 8(13). PMID: 28423487    Free PMC article.
Hallmarks of response to immune checkpoint blockade.
Alexandria P Cogdill, Miles C Andrews, Jennifer A Wargo.
Br J Cancer, 2017 May 20; 117(1). PMID: 28524159    Free PMC article.
Highly Cited. Review.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Rance C Siniard, Shuko Harada.
Virchows Arch, 2017 May 22; 471(2). PMID: 28528510
Review.
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Clemence Granier, Eleonore De Guillebon, +7 authors, Eric Tartour.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761757    Free PMC article.
Highly Cited. Review.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
John S Yi, Neal Ready, +15 authors, Kent J Weinhold.
Clin Cancer Res, 2017 Sep 28; 23(24). PMID: 28951518    Free PMC article.
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.
Chan-Young Ock, Jun-Eul Hwang, +12 authors, Ju-Seog Lee.
Nat Commun, 2017 Oct 21; 8(1). PMID: 29051489    Free PMC article.
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
Issa F Khouri, Irina Fernandez Curbelo, +7 authors, Padmanee Sharma.
Clin Cancer Res, 2017 Dec 17; 24(5). PMID: 29246938    Free PMC article.
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
David J Chung, Richard D Carvajal, +8 authors, James W Young.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296525    Free PMC article.
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Sonia Guedan, Avery D Posey, +14 authors, Carl H June.
JCI Insight, 2018 Jan 13; 3(1). PMID: 29321369    Free PMC article.
Highly Cited.
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Charlotte E Ariyan, Mary Sue Brady, +19 authors, James P Allison.
Cancer Immunol Res, 2018 Jan 18; 6(2). PMID: 29339377    Free PMC article.
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
Checks and Balances in Autoimmune Vasculitis.
Rebeca Hid Cadena, Wayel H Abdulahad, +4 authors, Elisabeth Brouwer.
Front Immunol, 2018 Mar 10; 9. PMID: 29520282    Free PMC article.
Review.
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
Su Yin Lim, Helen Rizos.
Mamm Genome, 2018 Jul 04; 29(11-12). PMID: 29968076    Free PMC article.
Review.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
Review.
Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
Pauline L de Goeje, Yarne Klaver, +7 authors, Rudi W Hendriks.
Front Immunol, 2018 Sep 25; 9. PMID: 30245692    Free PMC article.
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Silvia C Formenti, Nils-Petter Rudqvist, +15 authors, Sandra Demaria.
Nat Med, 2018 Nov 07; 24(12). PMID: 30397353    Free PMC article.
Highly Cited.
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Wouter Ouwerkerk, Mirjam van den Berg, +2 authors, Rosalie M Luiten.
Melanoma Res, 2019 Mar 12; 29(5). PMID: 30855527    Free PMC article.
Systematic Review.
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.
Amer M Zeidan, Hanna A Knaus, +17 authors, B Douglas Smith.
Clin Cancer Res, 2018 May 03; 24(15). PMID: 29716921    Free PMC article.
Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.
Heather M McGee, Megan E Daly, +14 authors, Arta M Monjazeb.
Int J Radiat Oncol Biol Phys, 2018 Jun 13; 101(5). PMID: 29891204    Free PMC article.
Immune checkpoint inhibitors: recent progress and potential biomarkers.
Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord.
Exp Mol Med, 2018 Dec 14; 50(12). PMID: 30546008    Free PMC article.
Highly Cited. Review.
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay, Christophe Caux.
J Immunother Cancer, 2019 Mar 30; 7(1). PMID: 30922400    Free PMC article.
Highly Cited. Review.
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma.
Hannah Yejin Kim, Parth J Upadhyay, +3 authors, Alan V Boddy.
Clin Pharmacokinet, 2019 Mar 15; 58(8). PMID: 30868471
Review.
Novel Radiation Therapy Paradigms and Immunomodulation: Heresies and Hope.
Suparna Dutt, Mansoor M Ahmed, Billy W Loo, Samuel Strober.
Semin Radiat Oncol, 2020 May 10; 30(2). PMID: 32381299    Free PMC article.
Review.
T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival.
Catherine A Bonham, Cara L Hrusch, +7 authors, Anne I Sperling.
Respir Med X, 2019 Jan 01; 1. PMID: 32455343    Free PMC article.
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors.
Iris Scherwitzl, Silvana Opp, +5 authors, Daniel Meruelo.
Mol Ther Oncolytics, 2020 Jun 02; 17. PMID: 32478167    Free PMC article.
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Lukas Amon, Lukas Hatscher, +2 authors, Christian H K Lehmann.
Pharmaceutics, 2020 Jul 18; 12(7). PMID: 32674488    Free PMC article.
Review.
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, Anna Spreafico.
Br J Clin Pharmacol, 2020 May 13; 86(9). PMID: 32394468    Free PMC article.
Review.
Combinatorial approach to cancer immunotherapy: strength in numbers.
Anna E Vilgelm, Douglas B Johnson, Ann Richmond.
J Leukoc Biol, 2016 Jun 04; 100(2). PMID: 27256570    Free PMC article.
Review.
The Clinical Trial Landscape for Melanoma Therapies.
Sonia Wróbel, Małgorzata Przybyło, Ewa Stępień.
J Clin Med, 2019 Mar 20; 8(3). PMID: 30884760    Free PMC article.
Review.
The Discovery of Biomarkers in Cancer Immunotherapy.
Anil P George, Timothy M Kuzel, Yi Zhang, Bin Zhang.
Comput Struct Biotechnol J, 2019 Apr 24; 17. PMID: 31011407    Free PMC article.
Review.
ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases.
Dan-Yang Li, Xian-Zhi Xiong.
Front Immunol, 2020 Sep 29; 11. PMID: 32983168    Free PMC article.
Review.
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.
Weilei Hu, Guosheng Wang, +2 authors, Ming You.
iScience, 2020 Oct 22; 23(10). PMID: 33083746    Free PMC article.
Review.
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Diane M Da Silva, Danielle M Enserro, +10 authors, W Martin Kast.
Clin Cancer Res, 2020 Aug 21; 26(21). PMID: 32816895    Free PMC article.
The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.
Luka de Vos, Ingela Grünwald, +7 authors, Dimo Dietrich.
Epigenetics, 2020 Apr 14; 15(11). PMID: 32281488    Free PMC article.
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
June Kyu Hwang, JinWoo Hong, Chae-Ok Yun.
Int J Mol Sci, 2020 Nov 20; 21(22). PMID: 33207653    Free PMC article.
Review.
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Hong Chen, Tihui Fu, +7 authors, Padmanee Sharma.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778280    Free PMC article.
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
Min Zhang, Jingwen Yang, +3 authors, Qijun Qian.
Front Med, 2019 Jan 27; 13(1). PMID: 30680606
Review.
The growing role of precision and personalized medicine for cancer treatment.
Paulina Krzyszczyk, Alison Acevedo, +13 authors, Martin L Yarmush.
Technology (Singap World Sci), 2019 Feb 05; 6(3-4). PMID: 30713991    Free PMC article.
Overcoming Immune Evasion in Melanoma.
Kevinn Eddy, Suzie Chen.
Int J Mol Sci, 2020 Dec 02; 21(23). PMID: 33256089    Free PMC article.
Review.
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Alexey Berezhnoy, Bradley J Sumrow, +16 authors, Paul A Moore.
Cell Rep Med, 2020 Dec 31; 1(9). PMID: 33377134    Free PMC article.
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
Sarah A O'Brien, Jessica Orf, +5 authors, Jackson G Egen.
Cancer Immunol Immunother, 2021 Jan 30; 70(8). PMID: 33511454    Free PMC article.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Jianjun Gao, Neema Navai, +28 authors, Padmanee Sharma.
Nat Med, 2020 Oct 14; 26(12). PMID: 33046869
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, +12 authors, Andrew D Weinberg.
Nat Commun, 2021 Feb 18; 12(1). PMID: 33594075    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Review.
Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Tatiana Cunha Pereira, Paulo Rodrigues-Santos, +7 authors, Gabriela Sousa.
Med Oncol, 2021 Apr 01; 38(5). PMID: 33788049
Review.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Craig L Slingluff, Hassane M Zarour, +13 authors, Jedd D Wolchok.
Oncoimmunology, 2021 Apr 03; 10(1). PMID: 33796406    Free PMC article.
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Colt Egelston, Weihua Guo, +9 authors, Yuan Yuan.
J Immunother Cancer, 2021 Mar 25; 9(3). PMID: 33757987    Free PMC article.
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?
Justine Cinier, Margaux Hubert, +5 authors, Christine Ménétrier-Caux.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33924428    Free PMC article.
Review.
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Meenal Sinha, Li Zhang, +14 authors, Lawrence Fong.
J Immunother Cancer, 2021 May 15; 9(5). PMID: 33986125    Free PMC article.
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Yoshinobu Koguchi, Noriko Iwamoto, +6 authors, William L Redmond.
J Immunother Cancer, 2021 Oct 09; 9(10). PMID: 34620702    Free PMC article.
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
Matthew T Campbell, Surena F Matin, +19 authors, Padmanee Sharma.
Nat Commun, 2021 Nov 06; 12(1). PMID: 34737281    Free PMC article.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A Ott, Matthew Nazzaro, +12 authors, F Stephen Hodi.
J Immunother Cancer, 2021 Nov 14; 9(11). PMID: 34772758    Free PMC article.
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Elena Goleva, Taras Lyubchenko, +3 authors, Jeffrey A Kern.
Ann Allergy Asthma Immunol, 2021 Mar 16; 126(6). PMID: 33716146    Free PMC article.
Review.
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.
Alexander C Huang, Roberta Zappasodi.
Nat Immunol, 2022 Mar 05; 23(5). PMID: 35241833    Free PMC article.
Review.
Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
Maria Davern, Noel E Donlon, +14 authors, Joanne Lysaght.
Transl Oncol, 2022 Apr 03; 20. PMID: 35366537    Free PMC article.